Armata Pharmaceuticals (ARMP) Liabilities and Shareholders Equity (2013 - 2026)

Armata Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 14 years of filings, most recently posting $69.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $69.8 million, down 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $317.0 million (down 16.63% YoY), and the FY2025 annual result was $76.9 million, down 11.05% from the prior year.
• Liabilities and Shareholders Equity came in at $69.8 million for Q1 2026 at Armata Pharmaceuticals, down from $76.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $120.4 million in Q1 2024 to a low of $69.8 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $98.2 million (2024), against an average of $96.2 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 117.67% in 2022 and decreased 27.51% in 2025, its largest moves.
• Armata Pharmaceuticals' Liabilities and Shareholders Equity stood at $95.8 million in 2022, then grew by 2.64% to $98.4 million in 2023, then dropped by 12.12% to $86.4 million in 2024, then dropped by 11.05% to $76.9 million in 2025, then dropped by 9.21% to $69.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $69.8 million (Q1 2026), $76.9 million (Q4 2025), and $89.5 million (Q3 2025), per Business Quant data.